書籍詳細

インスリン療法

P.3 掲載の参考文献

• 1) Holleman F, Hoekastra JBL:Insulin Lispro. New Engl J Med 337:176-183, 1997

• 2) Raskin P, Guthrie RA, Leiter L et al:Use of a fastacting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 23:583-588, 2000
  pubmed

• 3) Ratner RE, Hirsch IB, Neifing J et al:Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 23:639-643, 2000
  pubmed

P.5 掲載の参考文献

• 1) Early Treatment Diabetic Retinopathy Study Research Group:Grading diabetic retinopathy from stereoscopic color fundus photographs-anextension of the modified Airlie House classification:ETDRS report no.10. Ophthalmology 98:786-806, 1991

• 2) Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF et al:Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus:the Oslo study.BMJ 290:811-815, 1985
  pubmed

P.7 掲載の参考文献

• 1) The Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993

P.9 掲載の参考文献

• 1) The DCCT Research Group:The Diabetes Control and Complication Trials:results of the feasibility study. Diabetes Care 311:365-372, 1984

• 2) The DCCT Research Group:The Diabetes Control and Complication Trials:design and methodological considerations for the feasibility phase. Diabetes 35:530-545, 1986

• 3) The DCCT Research Group:Protcol for Diabetes Control and Complication Trials(DCCT). NIH publication no.88-2951.

P.11 掲載の参考文献

• 1) The Diabetes Control and Complications Trial(DCCT)Research Group:design and methodologic considerations for the feasibiblity phase. Diabetes 35:530-545,1986

• 2) DCCT Research Group:The effect of intensive treatment of diabetes on the development and progresssion of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993

P.13 掲載の参考文献

• 1) Bott S, Bott V, Berger M et al:Intensified insulin therapy and the risk of severe hypoglycaemia. Diabetologia 40:926-932, 1997

• 2) Sovic O, Thordarson H:Dead-in-bed syndrome in young diabetic patients. Diabetes Care 22 (suppl.2):B40-B42, 1999

P.15 掲載の参考文献

• 1) Glasgow RE, Eakin KG,Toobert DJ:How generalizable are the results of diabetes self-management research? The impact of participation and attrition. Diabetes Educ 22:573-585, 1996
  pubmed

• 2) Diabetes Control and Complications Trial Research Group:Effect of intensive treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus. J Pediatr 125:177-188, 1994

• 3) Thompson C, Cummings J, Chalmer J et al:How have patients reacted to the implications of the DCCT? Diabetes Care 19:876-879, 1996

• 4) Tamborlane WV, Gatcomb P, Held N et al:Implications of the DCCT results in treating children and adolescents with diabetes. Clin Diabetes 12:115-116, 1994

P.17 掲載の参考文献

• 1) The Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993

• 2) Leahy JC:Natural history of β-cell dysfunction. Diabetes Care 13:992-1010, 1990

• 3) Keller RJ, Eisenbarth GS, Jackson RA:Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 341:927-928, 1993
  pubmed

P.19 掲載の参考文献

• 1) Pozzilli P:Prevention of insulin-dependent diabetes:where are we now? Diabetes Metab Rev 12:127-135, 1996
  pubmed

• 2) Elliott RB, Chase HP:Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 34:362-365, 1991
  pubmed

• 3) Elliott RB, Pilcher CC, Fergusson DM et al:A population based strategy to prevent insulin dependent diabetes using nicotinamide. J Pediatr Endocrinol Metab 9:501-509, 1996
  pubmed

P.21 掲載の参考文献

• 1) Holleman F, Schmitt H, Rottiers R et al, the Benelux-UK Insulin Lispro Study Group:Reduced frequency of severe hypoglycemia and coma in well controlled IDDM patients treated with insulin lispro. Diabetes Care 20:1827-1832, 1997

• 2) Melki V, Renard E, Lassman-Vague V et al:Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care 21:977-982, 1998

P.23 掲載の参考文献

• 1) Holleman F, Schmitt H, Rottiers R et al and The Benelux-UK Insulin Lispro Study Group:Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with Insulin Lispro. Diabetes Care 20:1827-1832, 1997

• 2) Del Sindaco P, Ciofetta M, Lalli C et al:Use of the Short-acting Insulin Analogue Lispro in Intensive Treatment of Type 1 Diabetes Mellitus:Importance of Appropriate Replacement of Basal Insulin and Time-interval Injection-meal. Diabet Med 15:592-600, 1998
  pubmed

• 3) Lalli C, Ciofetta M, Del Sindaco P et al:Long-Term Intensive Treatment of Type 1 Diabetes With the Short-Acting Insulin Analog Lispro in Variable Combination With NPH Insulin at Mealtime. Diabetes Care 22:468-477, 1999
  pubmed

P.25 掲載の参考文献

• 1) Holleman F, Hoekstra JB:Insulin lispro.N Engl J Med 337:176-183, 1997
  pubmed

• 2) Howey DC, Bowsher RR, Brunelle RL et al:[Lys(B28), Pro(B29)]-human insulin:effect of injection time on postprandial glycemia. Clin Pharmacol Ther 58:459-469, 1995
  pubmed

P.27 掲載の参考文献

• 1) Rutledge KS, Chase HP, Klingensmith GJ et al:Effectiveness of postprandial Humalog in toddlers with diabetes. Pediatrics 100:968-972, 1997
  pubmed

• 2) Kotsanos JG, Vignati L, Huster W et al:Health related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy. Diabetes Care 20:948-958, 1997
  pubmed

P.29 掲載の参考文献

• 1) The Diabetes Control and Complications Trial Research Group:Influence of intensive diabetes treatment on quality-of-life outcomes in the Diabetes Control and Complications Trial. Diabetes Care 19:195-203, 1996

• 2) Bott U, Muhlhauser I, Overmann H et al:Validation of a Diabetes-Specific Quality-of-Life Scale for patients with type 1 diabetes. Diabetes Care 21:757-769, 1998
  pubmed

• 3) Guttmann-Bauman I, Flaherty B, Strugger M et al:Metabolic control and quality-of-life self-assessment in adolescents with IDDM. Diabetes Care 21:915-918, 1998
  pubmed

P.31 掲載の参考文献

• 1) The DCCT Research Group:Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual β-cell function:observations during eligibility testing for the Diabetes Control and Complications Trial(DCCT).J Clin Endocrinol Metab 65:30-36,1987

• 2) Schiffrin A, Desrosiers M, Belmonte M:Evaluation of two methods of self-blood glucose monitoring by trained insulin-dependent diabetic adolescents outside the hospital. Diabetes Care 6:166-169, 1983
  pubmed

P.35 掲載の参考文献

• 1) Rabinovitch A, Suarez WL, Thomas PD et al:Cytotoxic effects of cytokines on rat islets:evidence for involvement of free radicals and lipid peroxidation. Diabetologia 35:409-413, 1992
  pubmed

• 2) Pozzilli P, Maclaren NK:Immunotherapy at clinical diagnosis of insulin dependent diabetes. Trends Endocrinol Metab 4:101-105, 1993
  pubmed

• 3) Pozzilli P, Visalli N, Signore A et al:Double blind trial of nicotinamide in recent-onset IDDM(the IMDIAB III study)Diabetologia 38:848-852, 1995
  pubmed

P.37 掲載の参考文献

• 1) Knip M, Ilonen J, Mustonen A et al:Evidence of an accelerated β-cell destruction in HLA-Dw3/Dw4 heterozygous children with type 1(insulin-dependent)diabetes. Diabetologia 29:347-351, 1986

• 2) Sugihara S, Sakamaki T, Konda S et al:Association of HLA-DR, DQ genotype with different β-cell functions at IDDM diagnosis in Japanese children. Diabetes 46:1893-1897, 1997

• 3) Nakanishi K, Kobayashi T, Murase T et al:Human leukocyte antigen-A24 and-DQA1*0301 in Japanese insulin-dependent diabetes mellitus:independent contributions to susceptibility to the disease and additive contributions to acceleration of β-cell destruction. J Clin Endocrinol Metab 84:3721-3725, 1999

P.39 掲載の参考文献

• 1) Lembcke B:Pharmacodynamics of acarbose:clinical investigations. In Creutzfeldt W(ed)Acarbose for the treatment of diabetes mellitus. Springer-Verlag(Berlin), 1988,pp. 41-52

• 2) Laube H, Federlin K, Hillebrand I:Effect of α-inhibitors on blood glucose and insulin levels. Adv Exp Med Biol 246:287-293, 1988

• 3) Gerard J, Luyckx AS, Lefebvre]PJ:Improvement of metabolic control in insulin dependent diabetics treated with the α-glucosidase inhibitor acarbose for two months. Diabetologia 21:446-451, 1981

P.43 掲載の参考文献

• 1) Howey DC, Bowsher RR, Brunelle RL et al:[Lys(B28),Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 43:396-402, 1994
  pubmed

• 2) Anderson JH Jr, Brunelle RL, Koivisto VA et al:Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter lnsulin Lispro Study Group. Diabetes 46:265-270, 1997

• 3) Ronnemaa T, Laakso M, Puukka P et al:Atherosclerotic vascular disease in middle-aged, insulin-treated, diabetic patients:Association with endogenous insulin secretion capacity. Artherosclerosis 8:237-244, 1998

P.46 掲載の参考文献

• 1) Deckert T, Yokoyama H, Mathiesen E et al:Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes. BMJ 312:871-874, 1996
  pubmed

• 2) Mattock MB, Morrish NJ, Viberti G et al:Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 41:736-741, 1992
  pubmed

• 3) Yudkin JS, Forrest RD, Jackson CA:Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet ii:530-533, 1988

• 4) UKPDS:Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38. UK Prospective Diabetes Study Group.BMJ 317:703-713, 1998
  Medical*Online

P.49 掲載の参考文献

• 1) Kuusisto J, Mykkanen L, Pyorala K et al:NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43:960-967, 1994
  pubmed

• 2) ETDRS Investigators:Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14.JAMA 268:1292-1300, 1992
  pubmed

• 3) Uusitupa MI, Niskanen LK, Siitonen O et al:Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type2(non-insulin-dependent)diabetic and non-diabetic subjects. Diabetologia 36:1175-1184, 1993

P.51 掲載の参考文献

• 1) Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1979

• 2) Blackshear PJ, Rohde TD, Prosl F et al:The implantable infusion pump:a new concept in drug delivery. Med Prog Technol 6:149-161, 1979
  pubmed

• 3) Carlson MG, Campbell PJ:Intensive insulin therapy and weight gain in IDDM. Diabetes 42:1700-1707, 1993
  pubmed

P.53 掲載の参考文献

• 1) Jaremko J, Rorstad O:Advances toward the implantable artificial pancreas for treatment of diabetes. Diabetes Care 21:444-450, 1998
  pubmed

• 2) Belicar P, Lassmann-Vague V, The French EVADIAC Study Group:Local adverse events associated with long-term treatment by implantable insulin pumps. Diabetes Care 21:325-326, 1998

P.55 掲載の参考文献

• 1) Yki-Jarvinen H, Ryysy L, Kauppila M et al:Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:4037-4043, 1997
  pubmed

• 2) Yki-Jarvinen H, Kauppila M, Kujansuu E et al:Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 327:1426-1433, 1992
  pubmed

2型糖尿病インスリン療法以外(経口薬, 食事, 運動療法)

P.59 掲載の参考文献

• 1) Okada K, Hayashi T, Tsumura K et al:Leisure time physical activity at weekends and the risk of Type 2 diabetes mellitus in Japanese men:the Osaka Health Survey. Diabet Med 17:53-58, 2000
  pubmed

P.61 掲載の参考文献

• 1) Hanefeld M, Fischer S, Schulze J et al:Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 14:732-737,1991
  pubmed

• 2) Hollander P:Safety profile of acarbose, an alpha-glucosidase inhibitor. Drugs 44(suppl.3):47-53,1992

• 3) Zhou HH, Adedoyin A, Wilkinson GR:Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther 48:10-17,1990
  pubmed

P.64 掲載の参考文献

• 1) Bailey CJ, Turner RC:Metformin. N Engl J Med 334:574-579, 1996
  pubmed

• 2) Landin K, Tengborn L, Smith U:Metformin and metoprolol CR treatment in non-obese men. J Intern Med 235:335-341, 1994

• 3) Vague P, Juhan-Vague I, Alessi MC et al:Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 57:326-328, 1987
  pubmed

• 4) UK Prospective Diabetes Study(UKPDS)Group:Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS34). Lancet 352:854-865, 1998
  pubmed

• 5) Olsson J, Lindberg G, Gottsater M et al:Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination:a population-based observational study. Diabetologia 43:558-560, 2000
  pubmed

P.67 掲載の参考文献

• 1) Torjesen PA, Birkeland KI, Anderssen SA et al:Lifestyle changes may reverse development of the insulin resistance syndrome. The Oslo Diet and Exercise Study:a randomized trial. Diabetes Care 20:26-31, 1997
  pubmed

• 2) Eriksson KF, Lindgarde F:Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 34:891-898, 1991
  pubmed

• 3) Fujimoto WF:A national multicenter study to learn whether type II diabetes can be prevented:the Diabetes Prevention Program. Clin Diab 15:13-15, 1997

P.69 掲載の参考文献

• 1) Panzram G:Mortality and survival in type 2 diabetes mellitus. Diabetologia 30:123-131,1987
  pubmed

• 2) Smith DA:Comparative approaches to risk reduction of coronary heart disease in Tecumseh non-insulin-dependent diabetic population. Diabetes Care 9:601-608,1986
  pubmed

• 3) Graber AL, Christman BG, Alogna MT et al:Evaluation of diabetes patient-education programs. Diabetes 26:61-64, 1977
  pubmed

P.73 掲載の参考文献

• 1) Fujimoto WY, for the Diabetes Prevention Program Research Group:A national multicenter study to learn whether type II diabetes can be prevented:The Diabetes Prevention Program. Clinical Diabetes 15:13-19, 1997

• 2) 河津捷二, 門脇 孝:DPP(Diabetes Prevention Program)について, 分子糖尿病学の進歩-基礎から臨床まで-, 1997, pp210-218

P.75 掲載の参考文献

• 1) Wolffenbuttel BH, Nijst L, Sels JP et al:Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. Eur J Clin Pharmacol 45:113-116, 1993
  pubmed

• 2) Marbury TC, Hatorp V:Pharmacokinetics of repaglinide after single and multiple doses in patients with renal impairment compared with normal healthy volunteers(Abstract). Diabetes 47(suppl. 1):357A, 1998

• 3) Damsbo P, Andersen PH, Lund S et al:Improved glycaemic control with repaglinide in NIDDM with 3 times daily meal related dosing(Abstract). Diabetes 46(suppl. 1):34A, 1997

P.77 掲載の参考文献

• 1) Landry DW, Oliver JA:The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypotic lactic acidosis in dog. J Clin Invest 89:2071-2074, 1992

• 2) Muller G, Wied S:The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro. Diabetes 42:1852-1867, 1993
  pubmed

• 3) Bahr M, von Holtey M, Muller G et al:Direct stimulation of myocardial glucose transport and glucose transporter-1(GLUT 1)and GLUT 4 protein expression by the sulfonylurea glimepiride. Endocrinology 136:2547-2553, 1995

P.79 掲載の参考文献

• 1) Frost G, Dornhorst A:The relevance of the glycaemic index to our understanding of dietary carbohydrates. Diabet Med 17:336-345, 2000
  pubmed

• 2) Ludwig DS:Dietary glycemic index and obesity. J Nutr 130:280S-283S, 2000

• 3) Meyer KA, Kushi LH, Jacobs DR et al:Carbohydrates, dietary fiber, and incident type 2 diabetes in older women. Am J Clin Nutr 71:921-930, 2000
  pubmed

P.81 掲載の参考文献

• 1) National Institutes of Health:Consensus development conference on diet and exercise in non-insulin-dependent diabetes mellitus. Diabetes Care 10:639-644,1987
  pubmed

• 2) Bennett PH, Knowler WC:Early detection and intervention in diabetes mellitus:is it effective? J Chronic Dis 37:653-666,1984
  pubmed

• 3) Eriksson KF, Lindgarde F:Impaired glucose tolerance in a middle-aged male urban population:a new approach for identifying high-risk cases. Diabetologia 33:526-531,1990

P.83 掲載の参考文献

• 1) DeFronzo RA, Barzilai N, Simonson DC:Mechanism of metformin action in obese and iean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 73:1294-1301, 1991

• 2) Hermann LS, Melander A:Biguanides:basic aspects and clinical use:In:lnternational textbook of diabetes mellitus. Vol 1. Alberti KGM, DeFronzo RA, Keen H, Zimmet P eds, John Wiley, London, 1992, pp.773-795

P.85 掲載の参考文献

• 1) Kennedy JW, Hirshman MF, Gervino EV et al:Acute exercise induces GLUT4 translocation in skeletal muscle of normal human subjects and subjects with type 2 diabetes. Diabetes 48:1192-1197, 1999
  pubmed

P.87 掲載の参考文献

• 1) Uusitupa M, Louheranta A, Lindstrom J et al:The Finnish Diabetes Prevention Study. Br J Nutr 83(suppl. 1):S137-S142, 2000

• 2) Irwin ML, Mayer-Davis EJ, Addy CL et al:Moderate-intensity physical activity and fasting insulin levels in women:the Cross-Cultural Activity Participation Study. Diabetes Care 23:449-454, 2000
  pubmed

• 3) Taniguchi A, Fukushima M, Sakai M et al:Effect of physical training on insulin sensitivity in Japanese type 2 diabetic patients:role of serum triglyceride levels. Diabetes Care 23:857-858, 2000
  pubmed

P.89 掲載の参考文献

• 1) Pan XR, Li GW, Hu YH et al:Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997

• 2) Wing RR, Venditti E, Jakicic JM et al:Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care 21:350-359, 1998
  pubmed

• 3) Wing RR, Blair EH, Bononi P et al:Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 17:30-36, 1994
  pubmed

P.91 掲載の参考文献

• 1) Eriksson KF, Lindgarde F:Prevention of type 2(non-insulin-dependent)diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 34:891-898, 1991
  pubmed

• 2) Pan XR, Li GW, Hu YH et al:Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997

P.93 掲載の参考文献

• 1) Astrup A, Ryan L, Grunwald GK et al:The role of dietary fat in body fatness:evidence from a preliminary meta-analysis of ad libitum low-fat dietary intervention studies. Br J Nutr 83(suppl):S25-S32, 2000

• 2) Riccardi G, Rivellese AA:Dietary treatment of the metabolic syndrome-the optimal diet. Br J Nutr 83(suppl.1):S143-S148, 2000

• 3) Sorensen TI:The Changing lifestyle in the world. Body weight and what else? Diabetes Care 23(suppl.2):B1-B4, 2000

P.95 掲載の参考文献

• 1) Fonseca V, Foyt HL, Shen K et al:Long-term effects of troglitazone:open-label extension studies in type 2 diabetic patients. Diabetes Care 23:354-359, 2000
  pubmed

• 2) Krentz AJ, Bailey CJ, Melander A:Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials. BMJ 321:252-253, 2000
  pubmed

P.98 掲載の参考文献

• 1) Iwamoto Y, Kuzuya T, Matsuda A et al:Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14:1083-1086, 1991
  pubmed

• 2) Nagasaka S, Iwamoto Y, Ishikawa S et al:Efficacy of troglitazone measured by insulin resistance index. Lancet 350:184, 1997
  pubmed

• 3) Kumar S, Boulton AJ, Beck-Nielsen H et al:Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group. Diabetologia 39:701-709, 1996

• 4) Isshiki K, Haneda M, Koya D et al:Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 49:1022-1032, 2000
  pubmed

P.101 掲載の参考文献

• 1) Okuno A, Tamemoto H, Tobe K et al:Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361, 1998
  pubmed

P.103 掲載の参考文献

• 1) DCCT Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993

• 2) Ohkubo Y, Kishikawa H, Araki E et al:Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus:a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
  pubmed

• 3) University Group Diabetes Program:A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. Diabetes 25:1129-1153, 1976

P.105 掲載の参考文献

• 1) U.K Prospective Diabetes Study(UKPDS)Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). Lancet 352:837-853, 1998
  pubmed

P.107 掲載の参考文献

• 1) Jacobson AM, de Groot M, Samson JA:The evaluation of two measures of quality of life in patients with type I and type II diabetes. Diabetes Care 17:267-274, 1994
  pubmed

• 2) 石井 均, Bradley C, Riazi A ほか:糖尿病治療満足度質問表(DTSQ)の日本語訳と評価に関する研究. 医学のあゆみ 192:809-814, 2000

• 3) Jacobson AM, DCCT Research Group:The Diabetes Quality of Life Measure. Handbook of psychology and diabetes. In Bradley C(ed) Harwood Academic Publishers, Chur. pp65-87, 1994

P.109 掲載の参考文献

• 1) Nelson RG, Bennett PH, Beck GJ et al:Development and progression of renal disease in Pima Indians with non-insulin dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 335:1636-1642, 1996

P.111 掲載の参考文献

• 1) Laffel LM, McGill JB, Gans DJ:The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 99:497-504, 1995

• 2) Yusuf S, Peto R, Lewis J et al:Beta blockade during and after myocardial infarction:an overview of the randomized trials. Prog Cardiovasc Dis 27:335-371, 1985
  pubmed

P.113 掲載の参考文献

• 1) Johannesson M, Agewall S, Hartford M et al:The cost effectiveness of a cardiovascular multiple-risk-factor intervention programme in treated hypertensive men. J lntern Med 237:19-26, 1995

• 2) Edelson JT, Weinstein MC, Tosteson AN et al:Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 263:407-413, 1990
  pubmed

• 3) Nissinen A, Tuomilehto J, Kottke TE et al:Cost-effectiveness of the North Karelia Hypertension Program. Med Care 24:767-780, 1986
  pubmed

P.115 掲載の参考文献

• 1) Chiasson JL, Josse RG, Hunt JA et al:The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 121:928-935, 1994
  pubmed

• 2) U.K Prospective Diabetes Study(UKPDS)Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). Lancet 352:837-853, 1998
  pubmed

• 3) U.K Prospective Diabetes Study(UKPDS)Group:Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34). Lancet 352:854-865, 1998

P.117 掲載の参考文献

• 1) U.K Prospective Diabetes Study(UKPDS)Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). Lancet 352:837-853, 1998
  pubmed

• 2) U.K Prospective Diabetes Study(UKPDS)Group:Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34). Lancet 352:854-865, 1998

P.119 掲載の参考文献

• 1) Hanefeld M, Fischer S, Schulze J et al:Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 14:732-737, 1991
  pubmed

• 2) Reaven GM, Lardinois CK, Greenfield MS et al:Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care 13(suppl. 3):32-36, 1990

P.121 掲載の参考文献

• 1) Clissold SP, Edwards C:Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 35:214-243, 1988
  pubmed

• 2) Hagel J, Ruppin H, Pichl J et al:α-Glucosidase inhibitor acarbose:fate and effects in man. Gastroenterology 88:1410, 1985

• 3) Gerich JE:Oral hypoglycemic agents. N Engl J Med 321:1231-1245, 1989
  pubmed

P.123 掲載の参考文献

• 1) Bracken MB:Statistical methods for analysis of effects of treatment in overviews of randomized trials. In Effective Care of the Newborn Infant. Sinclair JC, Bracken MB, Eds., Oxford, U.K., Oxford University Press, 1992, pp.13-18

• 2) Bailey CJ,Turner RC:Drug therapy:metformin. N Engl J Med 334:574-579, 1996
  pubmed

P.125 掲載の参考文献

• 1) Faas A, Schellevis FG, Van Eijk JT:The efficacy of self-monitoring of blood glucose in NIDDM subjects. A criteria-based literature review. Diabetes Care 20:1482-1486, 1997
  pubmed

• 2) Atsumi Y, Kadowaki T et al:Self-monitoring blood glucose improves quolity of life in NIDDM patients treated with diet alone or oral hypoglycemic agents. Diabetes 46(suppl. 1):267A, 1997

P.127 掲載の参考文献

• 1) Asplund K, Wiholm BE, Lithner F:Glibenclamide-associated hypoglycaemia:a report on 57 cases. Diabetologia 24:412-417, 1983
  pubmed

• 2) Pulsinelli WA ,Levy DE, Sigsbee B et al:Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes mellitus. Am J Med 74:540-544,1983
  pubmed

• 3) Fontbonne A, Charles MA, Thibult N et al:Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population:the Paris Prospective Study, 15-year follow up. Diabetologia 34:356-361,1991

P.129 掲載の参考文献

• 1) Pasceri V, Wu HD, Willerson JT et al:Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101:235-238, 2000
  pubmed

• 2) Imano E, Kanda T, Nakatani Y et al:Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 21:2135-2139, 1998
  pubmed

• 3) Yoshimoto T, Naruse M, Nishikawa M et al:Antihypertensive and vasculo-and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 272:E989-E996, 1997
  pubmed

P.131 掲載の参考文献

• 1) Cavaghan MK, Ehrmann DA, Byrne MM et al:Treatment with the oral antidiabetic agent troglitazone improves β cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 100:530-537, 1997

• 2) Ehrmann DA, Schneider DJ, Sobel BE et al:Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82:2108-2116, 1997
  pubmed

• 3) Prigeon RL, Kahn SE, Porte D Jr:Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 83:819-823, 1998

P.133 掲載の参考文献

• 1) Inzucchi SE, Maggs DG, Spollett GR et al:Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867-872, 1998
  pubmed

• 2) Nagasaka S, Iwamoto Y, Ishikawa S et al:Efficacy of troglitazone measured by insulin resistance index. Lancet 350:184, 1997
  pubmed

• 3) Kuzuya T, Kosaka K, Akanuma Y et al:Baseline factors affecting the efficacy of troglitazone on plasma glucose in Japanese patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 41:121-129, 1998
  pubmed

P.135 掲載の参考文献

• 1) DCCT research group:Influence of intensive diabetes treatment on quality-of-life outcomes in the diabetes control and complications trial. Diabetes Care 19:195-213, 1996

• 2) de Sonnaville JJ, Snoek FJ, Colly LP et al:Well-being and symptoms in relation to insulin therapy in type 2 diabetes. Diabetes Care 21:919-924,1998
  pubmed

P.137 掲載の参考文献

• 1) Grant PJ:The effects of high-and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 19:64-66,1996

• 2) Goldberg RB, Holvey SM, Schneider J et al:A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care 19:849-856, 1996

• 3) Stenman S, Melander A, Groop PH et al:What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 118:169-172, 1993

P.139 掲載の参考文献

• 1) Hillebrand I:Pharmacological modification of digestion and absorption. Diabet Med 4:147-150, 1987
  pubmed

• 2) Hanefeld M, Fischer S, Schulze J et al:Therapeutic potentials of acarbose as first-line drug in NIDDM in sufficiently treated with diet alone. Diabetes Care 14:732-737, 1991

• 3) Reaven GM, Lardinois CK, Greenfield MS et al:Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care 13(suppl. 3):32-36, 1990

P.141 掲載の参考文献

• 1) Bakkali-Nadi A, Malaisse-Lagae F, Malaisse WJ:Insulinotropic action of meglitinide analogs:concentration-response relationship and nutrient dependency. Diabetes Res 27:81-87, 1994
  pubmed

• 2) Malaisse WJ:Stimulation of insulin release by non-sulfonylurea hypoglycemic agents:the meglitinide family. Horm Metab Res 27:263-266, 1995
  pubmed

P.143 掲載の参考文献

• 1) Kuzuya T, Iwamoto Y, Kosaka K et al:A pilot clinical trial of a new oral hypoglycemic agent,CS-045,in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 11:147-153,1991
  pubmed

• 2) Nagasaka S, Iwamoto Y, Ishikawa S et al:Efficacy of troglitazone measured by insulin resistance index. Lancet 350:184,1997
  pubmed

P.145 掲載の参考文献

• 1) DeFronzo RA Goodman AM:Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333:541-549,1995

• 2) Hermann LS, Schersten B, Bitzen PO et al:Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. Diabetes Care 17:1100-1109,1994
  pubmed

• 3) Goldberg RB, Einhorn D, Lucas CP et al:A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 21:1897-1903,1998
  pubmed

P.147 掲載の参考文献

• 1) Landgraf R, Bilo HJ, Muller PG:A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 55:165-171,1999
  pubmed

• 2) Damsbo P, Clauson P, Marbury TC et al:A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 22:789-794,1999
  pubmed

• 3) Wolffenbuttel BH, Landgraf R:A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 22:463-467,1999

合併症

P.151 掲載の参考文献

• 1) Mogensen CE:Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356-360,1984
  pubmed

• 2) Estacio RO, Jeffers BW, Hiatt WR et al:The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-652,1998
  pubmed

• 3) Estacio RO, Gifford N, Jefers BW et al:Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23(suppl. 2):B54-B64,2000

P.153 掲載の参考文献

• 1) Young MJ, Boulton AJ, MacLeod AF et al:A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 36:150-154,1993
  pubmed

• 2) Ziegler D, Hanefeld M, Ruhnau KJ et al:Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoicacid:a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 22:1296-1301,1999

P.155 掲載の参考文献

• 1) Lebovits HE, Wiegmann TB, Cnaan A et al:Renal protective effects of enalapril in hypertensive NIDDM:role of baseline albumiuria. Kidney Int Suppl 45:S150-S155,1994

• 2) Bakris GL, Weir MR, De Quattro V et al:Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 54:1283-1289,1998
  pubmed

P.157 掲載の参考文献

• 1) ETDRS Research Group:Photocoagulation for diabetic macular edema. ETDRS Report No.1. Arch Ophthalmol 103:1796-1806,1985

• 2) ETDRS Research Group:Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. ETDRS Report No.2. Ophthalmology 94:761-774,1987

• 3) Akduman L,Olk RJ:Subthreshold(invisible) modified grid diode laser photocoagulation in diffuse diabetic macular edema. Ophthalmic Surg Lasers 30:706-714,1999
  pubmed

P.159 掲載の参考文献

• 1) Shumer M, Burton G, Burtion C et al, The DCCT Study Group:Diabetic autonomic neuropathy-part I:autonomoic nervous system data analysis by a computerized central unit in a multi-centre tiral. Am J Med 85(suppl. SA):137-143,1988

P.161 掲載の参考文献

• 1) The Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986,1993

• 2) Reichard P, Britz A, Rosenqvist U:Intensified conventional insulin treatment and neuropsychological impairment. BMJ 303:1439-1442,1991
  pubmed

• 3) DCCT Research Group:A screening algorithm to identify clinically significant changes in neuropsychological functions in the Diabetes Control and Complications Trial. J Clin Exp Neuropsychol 16:303-316,1994

P.163 掲載の参考文献

• 1) Maser RE, Steenkiste AR, Dorman JS et al:Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 38:1456-1461,1989
  pubmed

• 2) Franklin GM, Kahn LB, Baxter J et al:Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study. Am J Epidemiol 131:633-643,1990

• 3) Neil HA,Thompson AV, John S et al:Diabetic autonomic neuropathy:the Prevalence of impaired heart rate variability in a geographically defined population. Diabet Med 6:20-24,1989

P.165 掲載の参考文献

• 1) Kannel WB, McGee DL:Diabetes and cardiovascular risk factors. The Framingham study. Circulation 59:8-13,1979
  pubmed

• 2) Mogensen CE:Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356-360,1984
  pubmed

• 3) Neil A, Hawkins M, Potok M et al:A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 16:996-1003,1993

• 4) The Acute Infarction Ramipril Efficacy(AIRE) Study Investigators:Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821-828,1993

P.167 掲載の参考文献

• 1) Robson MC, Phillips LG, Thomason A et al:Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 339:23-25,1992
  pubmed

• 2) Mustoe TA, Cutler NR, Allman RM et al:A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers. Arch Surg 129:213-219,1994
  pubmed

• 3) Steed DL and the Diabetic Ulcer Study Group:Clinical evaluation of recombinant platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 21:71-78,1995

P.169 掲載の参考文献

• 1) Rackley CE, Russell RO Jr, Rogers WJ et al:Clinical experience With glucose-insulin-potassium therapy in acute myocardial infarction. Am Heart J 102:1038-1049,1981
  pubmed

• 2) Tansey MJ, Opie LH:Relation between plasma free fatty acids and arrhythmias within the first twelve hours of acute myocardial infarction. Lancet 1:419-422,1983
  pubmed

• 3) Beta-blocker Heart Attack Trial Research Group:A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247:1707-1714,1982

P.171 掲載の参考文献

• 1) Dutta U, Padhy AK, Ahuja V et al:Double blind controlled trial of effect of cisapride on gastric emptying in diabetics. Trop Gastroenterol 20:116-119,1999
  pubmed

• 2) Patterson D, Abell T, Rothstein R et al:A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 94:1230-1234,1999
  pubmed

P.173 掲載の参考文献

• 1) The Diabetic Retinopathy Vitrectomy Study Research Group:Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. DRVS report #1. Ophthalmology 92:492-502,1985

• 2) The Diabetic Retinopathy Vitrectomy Study Research Group:Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. DRVS report #2. Arch Ophthalmol 103:1644-1652,1985

• 3) The Diabetic Retinopathy Vitrectomy Study Research Group:Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial-DRVS report #3. Ophthalmology 95:1307-1320,1988

P.175 掲載の参考文献

• 1) The Diabetes Control and Complications Trial Research group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986,1993

• 2) EDIC Research Group:Epidemiology of diabetes interventions and complications (EDIC):design,implementation,and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 22:99-111,1999

P.177 掲載の参考文献

• 1) ETDRS Group:Focal photocoagulation treatment of diabetic macular edema. Arch Ophthalmol 113:1144-1155,1995
  pubmed

• 2) ETDRS Group:Effects of aspirin treatment on diabetic retinopathy. Ophthalmol 98:757-765,1991

• 3) The DAMAD Study group:Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. Diabetes 38:491-498,1989

• 4) The TIMAD Study group:Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol 108:1577-1583,1990

P.179 掲載の参考文献

• 1) Lewis EJ, Hunsicker LG, Bain RP et al:The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462,1993
  pubmed

• 2) Miura J, Uchigata Y, Yokoyama H et al:Genetic polymorphyism of renin-angiotensin system is not associated with diabetic vascular complications in Japanese subjects with long-term insulin dependent diabetes mellitus. Diabetes Res Clin Pract 45:41-49,1999

• 3) Tarnow L, Kjeid T, Knudsen E et al:Lack of synergism between long-term poor glycaemic control and three gene polymorphisms of the renin angiotensin system on risk of developing diabetic nephropathy in type I diabetic patients. Diabetologia 43:794-799,2000

P.181 掲載の参考文献

• 1) Lewis EJ, Hunsicker LG, Bain RP et al:The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462,1993

P.183 掲載の参考文献

• 1) Hansson L, Lindholm LH, Niskaunen L et al:Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:the Captopril Prevention Project(CAPPP)randomised trial. Lancet 353:611-616,1999

• 2) Tuomilehto J, Rastenyte D, Birkenhager WH et al:Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 340:677-684,1999
  pubmed

• 3) Estacio RO, Jeffers BW, Hiatt WR et al:The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-652,1998
  pubmed

P.185 掲載の参考文献

• 1) 日本透析医学会:わが国の慢性透析療法の現況 (1998年12月31日現在). 1-665,1999

• 2) 厚生省循環器病委託「透析患者の循環器合併症の実態と対策に関する研究」研究班:透析患者に於ける虚血性心疾患の診断および治療指針. 透析会誌 29:249-250,1996

• 3) Sacks FM, Pfeffer MA, Moye LA et al:The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009,1996
  pubmed

• 4) The LIPID Study Group:Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357,1998

P.188 掲載の参考文献

• 1) Berelowitz M, Fischette C, Cefalu W et al:Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care 17:1460-1464,1994
  pubmed

• 2) Groop L, Luzi L, Melander A et al:Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes 36:1320-1328,1987
  pubmed

• 3) DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group:Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549,1995

P.191 掲載の参考文献

• 1) U.K. Prospective Diabetes Study Group:Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38. BMJ 317:703-713,1998

• 2) U.K. Prospective Diabetes Study Group:Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39. BMJ 317:713-720,1998

P.193 掲載の参考文献

• 1) The Diabetic Retinopathy Study Research Group:Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report number 8. Ophthalmology 88:583-600,1981

• 2) Marshall J, Bird AC:A comparative histological study of argon and krypton laser irradiations of the human retina. Br J Ophthalmol 63:657-668,1979

P.195 掲載の参考文献

• 1) The Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986,1993

• 2) U.K. Prospective Diabetes Study(UKPDS)Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 352:837-853,1998

• 3) Shichiri M, Kishikawa H, Ohkubo Y et al:Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 230(suppl. 2):B21-B29,2000

• 4) Wake N, Hisashige A, Katayama T et al:Cost-effectiveness of intensive insulin therapy for type 2 diabetes:a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract 48:201-210,2000
  pubmed

P.197 掲載の参考文献

• 1) Turner RC, Cull CA, Frighi V et al:Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus:progressive requirement for multiple therapies (UKPDS 49). U.K. Prospective Diabetes Study (UKPDS)Group. JAMA 281:2005-2012,1999
  pubmed

• 2) The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 41:416-423,1998
  pubmed

• 3) Ohkubo Y, Kishikawa H, Araki E et al:Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus:a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117,1995
  pubmed

P.199 掲載の参考文献

• 1) Rutter MK, McComb JM, Brady S et al:Silent myocardial ischemia and microalbuminuria in asymptomatic subjects with non-insulin-dependent diabetes mellitus. Am J Cardiol 83:27-31,1999
  pubmed

• 2) Beamer NB, Coull BM, Clark WM et al:Microalbuminuria in ischemic stroke. Arch Neurol 56:699-702,1999
  pubmed

P.203 掲載の参考文献

• 1) Yusuf S, Sleight P, Pogue J et al:Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153,2000

• 2) Yusuf S, Dagenais G, Pogue J et al:Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:154-160,2000

• 3) Gerstein HC:Cardiovascular and metabolic benefits of ACE inhibition:moving beyond blood pressure reduction. Diabetes Care 23:882-883,2000
  pubmed

• 4) Kshirsagar AV, Joy MS, Hogan SL et al:Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease:a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 35:695-707,2000
  pubmed

• 5) Pahor M, Psaty BM,Alderman MH et al:Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 23:888-892,2000
  pubmed

P.205 掲載の参考文献

• 1) Reichard P, Nilsson BY, Rosenqvist U:The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309,1993
  pubmed

• 2) The Diabetes Control and Complications Trial Research Group:Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial. Ann Intern Med 124:379-388,1996

P.207 掲載の参考文献

• 1) Ignarro LJ, Bush PA, Buga GM et al:Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 170:843-850,1990
  pubmed

• 2) Goldstein I, Lue TF, Padma-Nathan H et al:Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. Published erratum appears in N Engl J Med 338:1397-1404,1998

• 3) Price DE, Gingell JC, Gepi-Attee S et al:Sildenafil:study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med 15:821-825,1998
  pubmed

P.209 掲載の参考文献

• 1) Gabbay KH:The sorbitol pathway and the complications of diabetes. N Engl J Med 288:831-836,1973
  pubmed

• 2) Cogan DG, Kinoshita JH, Kador PF et al:NIH conference. Aldose reductase and complications of diabetes. Ann Intern Med 101:82-91,1984
  pubmed

• 3) Kennedy A, Frank RN, Varma SD:Aldose reductase activity in retinal and cerebral microvessels and cultured vascular cells. Invest Ophthalmol Vis Sci 24:1250-1258,1983
  pubmed

P.211 掲載の参考文献

• 1) 石川 信:糖尿病における血小板機能異常-In vitro血小板機能及び放出能の血小板凝集抑制剤に対する変化-. 糖尿病 32:649-656,1989

• 2) 久保 明:糖尿病における血小板活性化状態-網膜症の進展との関連-糖尿病 31:149-155,1988

P.213 掲載の参考文献

• 1) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes:Sections I and II. University Group Diabetes Program. Diabetes 19(suppl. 2):747-830,1970

• 2) Report of the Committe for the Assessment of Biometric Aspects of Controlled Trials of Hypoglycemic Agents. JAMA 231:583-608,1975

• 3) Knattterud G I, Klimt C R, Levin M E et al:Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes:VII. Mortality and selected nonfatal events with insulin treatment JAMA 240:37-42,1978

P.215 掲載の参考文献

• 1) Abraira C, Emanuele N, Colwell J et al:Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group. Diabetes Care 15:1560-1571,1992
  pubmed

• 2) Early Treatment Diabetic Retinopathy Study Research Group:Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 98(suppl):823-833,1991

• 3) Reichard P, Nilsson BY, Rosenqvist U:The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309,1993
  pubmed